TELA
TELA Bio, Inc.
$0.8500
-3.41%
$38.1M
No data for this timeframe.
Vol
Market Cap$38.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders5 funds
Inst. Value$2.3M
Inst. Activity1 buys / 0 sells
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001561921·Prev Close $0.8800
Recent Activity
May 12, 2026
SEC
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M preliminary estimate, and a net loss of
8-K — Impact 4/10
May 12, 2026
SEC
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP),
PRESS-RELEASE — Impact 6/10
May 12, 2026
earnings
TELA Bio Reports First Quarter 2026 Financial Results
<p align="left">MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a comm
Apr 30, 2026
SEC
TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but the filing is dominat
8-K — Impact 6/10
Feb 24, 2026
Insider
KOBLISH ANTONY sold 3,900 shares
Chief Executive Officer @ $0.7852 ($3.1K)
Feb 23, 2026
Insider
Firestone Gregory A. sold 1,352 shares
Chief Business Officer @ $0.7660 ($1.0K)
Feb 23, 2026
Insider
Smeykal Megan sold 423 shares
Chief Accounting Officer @ $0.7660 ($324.02)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
128,700 shares ($151.9K)
Price Targets
$2.25
+140.6% upside
Strong Buy
Current $0.9352
Low $1.00
Median $2.00
High $3.25
5 analysts
$1.00
$3.25
Analyst Ratings
3Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 25, 2026 | Piper Sandler | MAINTAIN | Neutral → Neutral |
| Mar 25, 2026 | Lake Street | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.18 ▼ -1.1% | $-0.20 — $-0.15 | 19% YoY | 5 |
| Next Q | $-0.15 ▲ +7.4% | $-0.16 — $-0.14 | 21% YoY | 5 |
| Current FY | $-0.67 ▲ +0.9% | $-0.69 — $-0.62 | 20% YoY | 5 |
| Next FY | $-0.56 ▲ +1.1% | $-0.63 — $-0.47 | 17% YoY | 5 |
Latest Reports
MIXED
8-K
4/10
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M preliminary estimate, and a net loss of
May 12, 2026
BEARISH
PRESS-RELEASE
6/10
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP),
May 12, 2026
NEUTRAL
Press
3/10
TELA Bio reported financial results for Q4 and full year 2025. The press release announces earnings but contains no actu
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $151.9K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $5.0K | EXIT |
| MORGAN STANLEY | $2.6K | NEAR_EXIT |
| BANK OF AMERICA CORP | $42.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 24, 2026 | KOBLISH ANTONY | F | $3.1K |
| Feb 23, 2026 | Firestone Gregory | F | $1.0K |
| Feb 23, 2026 | Smeykal Megan | F | $324.02 |
| Feb 23, 2026 | Cuca Roberto | F | $4.0K |
| Feb 23, 2026 | KOBLISH ANTONY | F | $8.9K |
5 institutional holders with $2.3M total value (1,965,705 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,830,550 | $2.2M | 93.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 128,700 | $151.9K | 6.5% | DOUBLED +101.4% |
| 3 | WELLS FARGO & COMPANY/MN | 4,200 | $5.0K | 0.2% | EXIT -100.0% |
| 4 | MORGAN STANLEY | 2,219 | $2.6K | 0.1% | NEAR_EXIT -94.3% |
| 5 | BANK OF AMERICA CORP /DE/ | 36 | $42.00 | 0.0% | NEAR_EXIT -89.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 63,900 | 128,700 | +101.4% | $151.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 330 | 35 | -89.4% | $52.00 | 2025-Q3 |
| UBS Group AG | TRIM | 330,683 | 245,548 | -25.7% | $476.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 244,444 | 67,333 | -72.5% | $130.6K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 39,120 | 2,219 | -94.3% | $4.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 252 | 330 | +31.0% | $641.00 | 2025-Q2 |
| UBS Group AG | TRIM | 767,830 | 330,683 | -56.9% | $403.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 425,140 | 244,444 | -42.5% | $298.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 60,510 | 91,106 | +50.6% | $111.1K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 17,822 | 39,120 | +119.5% | $47.7K | 2025-Q1 |
| UBS Group AG | NEW | — | 767,830 | — | $2.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 148,900 | 425,140 | +185.5% | $1.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 23,362 | 60,510 | +159.0% | $182.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 2,220 | 17,822 | +167.6% | $53.8K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | EXIT | 16,718 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 19,617 | 2,220 | -88.7% | $5.6K | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | KOBLISH ANTONY | Chief Executive Officer | F | 3,900 | $0.7852 | $3.1K |
| Feb 23, 2026 | Firestone Gregory A. | Chief Business Officer | F | 1,352 | $0.7660 | $1.0K |
| Feb 23, 2026 | Smeykal Megan | Chief Accounting Officer | F | 423 | $0.7660 | $324.02 |
| Feb 23, 2026 | Cuca Roberto | COO and CFO | F | 5,234 | $0.7660 | $4.0K |
| Feb 23, 2026 | KOBLISH ANTONY | Chief Executive Officer | F | 11,631 | $0.7660 | $8.9K |
| Feb 23, 2026 | Talmo Paul | Chief Technology Officer | F | 4,061 | $0.7660 | $3.1K |
| Feb 21, 2026 | Talmo Paul | Chief Technology Officer | F | 3,385 | $0.7174 | $2.4K |
| Feb 21, 2026 | KOBLISH ANTONY | Chief Executive Officer | F | 12,494 | $0.7174 | $9.0K |
| Feb 21, 2026 | Smeykal Megan | Chief Accounting Officer | F | 1,590 | $0.7174 | $1.1K |
| Feb 21, 2026 | Cuca Roberto | COO and CFO | F | 4,780 | $0.7174 | $3.4K |
| Feb 21, 2026 | Firestone Gregory A. | Chief Business Officer | F | 4,189 | $0.7174 | $3.0K |
| Feb 20, 2026 | Blizard Jeffrey | President | A | 86,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Blizard Jeffrey | President | A | 127,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Firestone Gregory A. | Chief Business Officer | A | 55,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Cuca Roberto | COO and CFO | A | 85,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Talmo Paul | Chief Technology Officer | A | 57,000 | $0.00 | $0.00 |
| Feb 20, 2026 | KOBLISH ANTONY | Chief Executive Officer | A | 176,000 | $0.00 | $0.00 |
| Feb 20, 2026 | KOBLISH ANTONY | Chief Executive Officer | A | 261,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Cuca Roberto | COO and CFO | A | 57,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Firestone Gregory A. | Chief Business Officer | A | 37,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Talmo Paul | Chief Technology Officer | A | 85,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Smeykal Megan | Chief Accounting Officer | F | 795 | $0.7950 | $632.02 |
| Feb 18, 2026 | Smeykal Megan | Chief Accounting Officer | A | 32,850 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 2 mixed, 1 neutral. Avg impact: 4.8/10.
MIXED
8-K
4/10
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M preliminary estimat
May 12, 2026
BEARISH
PRESS-RELEASE
6/10
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an E
May 12, 2026
MIXED
8-K
6/10
TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but t
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
3/10
TELA Bio announced it will report Q1 2026 financial results on May 12, 2026, with a conference call
Apr 21, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 3 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.25 mean target
+140.6% upside
Strong Buy (3.00)
$1.00 Low
$3.25 High
| Metric | Value |
|---|---|
| Current Price | $0.9352 |
| Target Low | $1.00 |
| Target Mean | $2.25 |
| Target Median | $2.00 |
| Target High | $3.25 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.18 | $-0.20 | $-0.15 | 19.1% | -1.1% | 0↑ 1↓ | $0.0B | -0.9% | 5 |
| Next Q 2026-09-30 |
$-0.15 | $-0.16 | $-0.14 | 21.0% | +7.4% | 1↑ 1↓ | $0.0B | 10.0% | 5 |
| Current FY 2026-12-31 |
$-0.67 | $-0.69 | $-0.62 | 19.5% | +0.9% | 1↑ 1↓ | $0.1B | 8.0% | 5 |
| Next FY 2027-12-31 |
$-0.56 | $-0.63 | $-0.47 | 16.8% | +1.1% | 1↑ 1↓ | $0.1B | 10.4% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.178 | |
| 7d ago | $0.000 | -0.178 |
| 30d ago | $-0.176 | -0.002 |
| 60d ago | $-0.150 | -0.028 |
| 90d ago | $-0.150 | -0.028 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 25, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Mar 25, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
TELA Bio Reports First Quarter 2026 Financial Results
<p align="left">MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on
May 12, 2026
earnings_calendar
TELA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 30, 2026
earnings
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
<p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused
Apr 21, 2026
earnings
TELA Bio to Announce First Quarter 2026 Financial Results
<p>MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focuse
Mar 24, 2026
earnings
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
<p>MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing
Mar 24, 2026
earnings_calendar
TELA Q4 2025 Earnings After Market Close — 2026-03-24
Mar 10, 2026
earnings
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
<p>MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focuse